Breakdown | |||||
TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
475.95M | 451.80M | 368.17M | 303.43M | 252.02M | 203.22M | Gross Profit |
347.21M | 328.82M | 261.04M | 215.64M | 184.16M | 149.96M | EBIT |
20.36M | 12.23M | -16.75M | 5.12M | 38.76M | -20.42M | EBITDA |
25.87M | 24.41M | -6.82M | 5.12M | 31.95M | -18.15M | Net Income Common Stockholders |
428.99M | 424.38M | -21.63M | -6.70M | -8.09M | -44.23M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
282.85M | 255.49M | 296.22M | 255.61M | 254.60M | 61.09M | Total Assets |
1.29B | 1.17B | 558.74M | 483.84M | 344.36M | 115.56M | Total Debt |
69.55M | 71.92M | 72.08M | 76.60M | 53.91M | 424.90M | Net Debt |
-205.61M | -105.43M | -149.69M | -174.13M | -200.69M | 363.82M | Total Liabilities |
142.72M | 139.34M | 149.09M | 145.45M | 82.27M | 460.17M | Stockholders Equity |
1.12B | 1.01B | 354.33M | 269.52M | 197.03M | -344.61M |
Cash Flow | Free Cash Flow | ||||
83.50M | 69.06M | 78.98M | 50.25M | -1.67M | -10.29M | Operating Cash Flow |
88.78M | 74.32M | 84.60M | 58.01M | 3.36M | -6.49M | Investing Cash Flow |
55.68M | -55.65M | -95.06M | -76.55M | -5.03M | -3.81M | Financing Cash Flow |
-58.77M | -61.67M | -19.29M | 16.23M | 195.29M | 51.04M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
80 Outperform | $8.46B | 48.06 | 39.29% | 0.12% | 14.29% | 151.38% | |
78 Outperform | $6.26B | 13.28 | 58.14% | ― | 23.21% | ― | |
75 Outperform | $8.15B | 109.43 | 25.23% | ― | 18.63% | -55.09% | |
65 Neutral | $5.85B | 235.54 | -19.65% | ― | 15.20% | -666.94% | |
62 Neutral | $11.80B | 10.10 | -7.47% | 2.99% | 7.37% | -8.16% | |
61 Neutral | $6.82B | 413.54 | 2.53% | ― | 29.31% | ― | |
51 Neutral | $3.58B | ― | -33.09% | ― | 13.85% | 3.47% |
On April 21, 2025, Clearwater Analytics completed its acquisition of Enfusion, valued at approximately $1.5 billion. This strategic move positions Clearwater as the first unified, cloud-native front-to-back platform for institutional investors, enhancing its market position by integrating Enfusion’s front-office capabilities with its existing middle and back-office solutions. The acquisition is expected to expand Clearwater’s total addressable market and international presence, offering seamless integration and operational efficiency across asset classes and geographies.